Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab.
Kelly
Ronan J
RJ
National Cancer Institute, Mark O. Hatfield Clinical Research Center, Bethesda, MD, USA.
Carter
Corey
C
Giaccone
Giuseppe
G
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D057285:Precision Medicine; D052999:Quinazolinones / Q000008:administration & dosage*; D000068878:Trastuzumab; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052999:Quinazolinones; C525726:dacomitinib; D014747:Vinblastine; D000068878:Trastuzumab; D000077235:Vinorelbine